Ph 2 ARASEC Data Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic CSPC May 21, 2026
Supplemental NDA submitted in Japan for PADCEV + Keytruda in Cisplatin-Eligible Patients with MIBC May 21, 2026
CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline May 21, 2026
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic HSPC May 21, 2026
US FDA Approves INQOVI® in Combination with Venetoclax in AML Patients Ineligible for Intensive Induction Chemo May 21, 2026
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas May 21, 2026
Extended Clinical Benefit Over Multiple Clinical Endpoints Reported from Ph 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at longer Follow-up May 21, 2026
FDA Grants Priority Review to Supplemental NDA for HYRNUO® (sevabertinib) Under Investigation in 1L HER2-Mutated NSCLC May 21, 2026
Enhertu approved for use before surgery based on DESTINY-Breast11 Ph 3 trial and following surgery based on DESTINY-Breast05 Ph 3 trial in HER2-positive early breast cancer May 21, 2026
Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan in Gastrointestinal Tumors May 21, 2026
Rigel Enters Licensing Agreement for VEPPANU™ (vepdegestrant) for 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer May 21, 2026
First interim unblinding expected in June 2026 following 45 subject enrollment milestone achieved in MIRACLE trial May 21, 2026
Updated Interim Results Announced From Ph 2 LEGEND trial of detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC patients with CIS with or without concomitant papillary disease May 21, 2026
ZUSDURI Median DOR Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial May 21, 2026
Ph 3 VIKTORIA-2 Trial of Gedatolisib in 1L HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients May 21, 2026
Perioperative Imfinzi plus neoadjuvant EV showed statistically significant EFS/OS improvements in MIBC in Ph 3 VOLGA trial May 21, 2026
Positive Updated 12-Month Data Demonstrated Durable Responses in BCG-Naïve Cohort of Ph 2 ADVANCED-2 Trial of TARA-002 in NMIBC May 21, 2026
94.5% Six-Month Duration of Response reported from Ph 3 UTOPIA Trial of UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC May 21, 2026
Re-induction with ADSTILADRIN resulted in complete responses in 31% of initial non-responders with BCG-unresponsive NMIBC May 21, 2026
